Stocks of Dexcom Inc (NASDAQ:DXCM) traded higher last session on Wall Street, up 4.62% to $88.83.
DXCM stock price is now -4.21% away from the 50-day moving average and -20.75% away from the 200-day moving average. The market capitalization of the company currently stands at $34.32B.
In other news, Pacelli Steven Robert, EVP Managing Director Dexcom V sold 411 shares of the company’s stock on Oct 23. The stock was sold for $35,243 at an average price of $85.75. Upon completion of the transaction, the EVP Managing Director Dexcom V now directly owns 125,186 shares in the company, valued at $11.12 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 16, Director ALTMAN STEVEN R sold 1,000 shares of the business’s stock. A total of $77,580 was realized by selling the stock at an average price of $77.58. This leaves the insider owning 60,700 shares of the company worth $5.39 million. Insiders disposed of 479,606 shares of company stock worth roughly $42.6 million over the past 1 year. A total of 1.53% of the company’s stock is owned by insiders.
Tuesday’s opening bell rang with an opening price of $85.73 for Dexcom Inc (NASDAQ: DXCM). During the past 12 months, Dexcom Inc has had a low of $74.75 and a high of $139.55. As of last week, the company has a debt-to-equity ratio of 1.20, a current ratio of 2.80, and a quick ratio of 2.50. According to the stock market information, the enterprise value for the company is $33.80B, which is based on a 98.40 price-to-earnings ratio, a 2.90 price-to-earnings-growth ratio, and a beta of 1.14. The fifty day moving average price for DXCM is $92.42 and a two-hundred day moving average price translates $111.99 for the stock.
The latest earnings results from Dexcom Inc (NASDAQ: DXCM) was released for Sep, 2023. According to the Medical Devices Company, earnings per share came in at $0.34, beating analysts’ expectations of $0.23 by 0.11. This compares to $0.24 EPS in the same period last year. The net profit margin was 11.08% and return on equity was 18.42% for DXCM. The company reported revenue of $975.0 million for the quarter, compared to $769.6 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 26.69 percent. For the current quarter, analysts expect DXCM to generate $939.24M in revenue.
Dexcom Inc(DXCM) Company Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
